<![CDATA[Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. The increasing prevalence of diabetes and limitations of current therapies have encouraged the development of plant-based antidiabetic agents. One promising medicinal plant is Tinospora crispa, which contains various secondary metabolites with reported antihyperglycemic activity. This study aimed to investigate the antidiabetic potential of Tinospora crispa bioactive compounds through network pharmacology and molecular docking approaches. The study was conducted in silico using PubChem, SwissADME, pkCSM, SuperPred, GeneCards, and STRING databases, as well as Cytoscape, PyRx, AutoDockTools, and Discovery Studio Visualizer software. A total of 51 secondary metabolites were identified, of which 33 compounds had available SMILES data and 21 compounds met drug-likeness and favorable pharmacokinetic criteria. Target prediction identified 495 protein targets, while disease target screening yielded 615 diabetes mellitus-related genes. Intersection analysis revealed 16 overlapping genes potentially involved in the antidiabetic mechanism of Tinospora crispa. Protein–protein interaction network and topological analyses identified mTOR as the primary hub gene, showing the highest degree centrality, betweenness centrality, and closeness centrality values. Molecular docking demonstrated that β-stigmasterol showed the strongest binding affinity toward the mTOR receptor, with a binding energy of −8.29 kcal/mol. These findings suggest that Tinospora crispa has potential as an antidiabetic agent by modulating glucose metabolism, energy homeostasis, and insulin signaling pathways, providing a scientific basis for further molecular dynamics simulations and in vitro and in vivo evaluations.]]>
